期刊
BREAST CANCER RESEARCH
卷 6, 期 3, 页码 R149-R156出版社
BMC
DOI: 10.1186/bcr767
关键词
breast cancer; breast carcinoma; infiltrating ductal carcinoma; infiltrating lobular carcinoma; invasive ductal carcinoma of the breast; invasive lobular carcinoma of the breast; special type of breast cancer
类别
资金
- NATIONAL CANCER INSTITUTE [P50CA058183, P01CA030195] Funding Source: NIH RePORTER
- NCI NIH HHS [P01 CA030195, P50 CA058183, P01 CA30195, P50 CA58183] Funding Source: Medline
Introduction: Invasive lobular carcinoma (ILC) comprises approximately 10% of breast cancers and appears to have a distinct biology. Because it is less common than infiltrating ductal carcinoma (IDC), few data have been reported that address the biologic features of ILC in the context of their clinical outcome. In the present study we undertook an extensive comparison of ILC and IDC using a large database to provide a more complete and reliable assessment of their biologic phenotypes and clinical behaviors. Methods: The clinical and biological features of 4140 patients with ILC were compared with those of 45,169 patients with IDC ( not otherwise specified). The median follow-up period was 87 months. Results: In comparison with IDC, ILC was significantly more likely to occur in older patients, to be larger in size, to be estrogen and progesterone receptor positive, to have lower S-phase fraction, to be diploid, and to be HER-2, p53, and epidermal growth factor receptor negative. It was more common for ILC than for IDC to metastasize to the gastrointestinal tract and ovary. The incidence of contralateral breast cancer was higher for ILC patients than for IDC patients (20.9% versus 11.2%; P < 0.0001). Breast preservation was modestly less frequent in ILC patients than in IDC patients. The 5-year disease-free survival was 85.7% for ILC and 83.5% for IDC ( P = 0.13). The 5-year overall survival was 85.6% for ILC and 84.1% for IDC ( P = 0.64). Conclusion: Despite the fact that the biologic phenotype of ILC is quite favorable, these patients do not have better clinical outcomes than do patients with IDC. At present, management decisions should be based on individual patient and tumor biologic characteristics, and not on lobular histology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据